108 related articles for article (PubMed ID: 14675310)
1. Molecular similarities between primary peritoneal and primary ovarian carcinomas.
Chen LM; Yamada SD; Fu YS; Baldwin RL; Karlan BY
Int J Gynecol Cancer; 2003; 13(6):749-55. PubMed ID: 14675310
[TBL] [Abstract][Full Text] [Related]
2. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
3. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma.
Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R
Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845
[TBL] [Abstract][Full Text] [Related]
4. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
Tomić S; Ilić Forko J; Babić D; Sundov D; Kuret S; Andelinović S
Croat Med J; 2003 Aug; 44(4):429-34. PubMed ID: 12950146
[TBL] [Abstract][Full Text] [Related]
5. Peritoneal serous papillary carcinoma, a phenotypic variant of familial ovarian cancer: implications for ovarian cancer screening.
Karlan BY; Baldwin RL; Lopez-Luevanos E; Raffel LJ; Barbuto D; Narod S; Platt LD
Am J Obstet Gynecol; 1999 Apr; 180(4):917-28. PubMed ID: 10203660
[TBL] [Abstract][Full Text] [Related]
6. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
[TBL] [Abstract][Full Text] [Related]
7. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
8. nm23 expression in advanced and borderline ovarian carcinoma.
Schneider J; Romero H; Ruiz R; Centeno MM; Rodriguez-Escudero FJ
Anticancer Res; 1996; 16(3A):1197-202. PubMed ID: 8702236
[TBL] [Abstract][Full Text] [Related]
9. P53, bcl-2, and nm23 expressions in serous ovarian tumors: correlation with the clinical and histopathological parameters.
Arik D; Kulaçoğlu S
Turk Patoloji Derg; 2011 Jan; 27(1):38-45. PubMed ID: 21469425
[TBL] [Abstract][Full Text] [Related]
10. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
11. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
12. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer.
Demirbaş S; Sücüllü I; Yildirim S; Celenk T
Turk J Gastroenterol; 2006 Mar; 17(1):13-9. PubMed ID: 16830272
[TBL] [Abstract][Full Text] [Related]
13. Demographic clinical and prognostic characteristics of primary ovarian, peritoneal and tubal adenocarcinomas of serous histology--a prospective comparative study.
Schnack TH; Sørensen RD; Nedergaard L; Høgdall C
Gynecol Oncol; 2014 Nov; 135(2):278-84. PubMed ID: 25168689
[TBL] [Abstract][Full Text] [Related]
14. [A study on C-erbB2, nm23 and p53 expressions in epithelial ovarian cancer and their clinical significance].
Liu L; Yang K
Zhonghua Fu Chan Ke Za Zhi; 1999 Feb; 34(2):101-4. PubMed ID: 11263193
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical study of p53, c-erbB-2 and nm23 proteins in human gastric cancer].
Wei Z; Wu Y; Zhai Z
Zhonghua Zhong Liu Za Zhi; 1997 Sep; 19(5):378-81. PubMed ID: 10920922
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
18. Elevated nm23 protein expression is correlated with diminished progression-free survival in patients with epithelial ovarian carcinoma.
Srivatsa PJ; Cliby WA; Keeney GL; Dodson MK; Suman VJ; Roche PC; Podratz KC
Gynecol Oncol; 1996 Mar; 60(3):363-72. PubMed ID: 8774640
[TBL] [Abstract][Full Text] [Related]
19. Suppressive role of the metastasis-related nm23-H1 gene in human ovarian carcinomas: association of high messenger RNA expression with lack of lymph node metastasis.
Viel A; Dall'Agnese L; Canzonieri V; Sopracordevole F; Capozzi E; Carbone A; Visentin MC; Boiocchi M
Cancer Res; 1995 Jun; 55(12):2645-50. PubMed ID: 7780979
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach.
Patel DD; Bhatavdekar JM; Chikhlikar PR; Patel YV; Shah NG; Ghosh N; Suthar TP; Balar DB
J Surg Oncol; 1997 Jun; 65(2):111-6. PubMed ID: 9209522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
